ArticleFrontiers in oncology2025
Risk factors of pathologic complete response for neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Immune-inflammatory indices as predictors of pathologic complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review and meta-analysis of observational studies.World journal of surgical oncology · 2026Pooled it
- Predicting treatment response to neoadjuvant chemotherapy in locally advanced rectal cancer: A combined deep learning and machine learning approach utilizing longitudinal multi-sequence MRI.European journal of radiology open · 2026Article
- Integrating CT-Based Radiomics Analysis With Serum CEA Level to Predict Neoadjuvant Chemoradiotherapy Response in Colorectal Cancer.The Kaohsiung journal of medical sciences · 2026Article
- Predictors of survival for locally advanced rectal cancer patients with poor response to neoadjuvant chemoradiotherapy.Radiation oncology (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Global cancer statistics indicate colorectal cancer as the second leading cause of cancer-related deaths, with rectal cancer accounting for approximately 30% of cases. Despite neoadjuvant chemoradiotherapy (nCRT) being standard for locally advanced rectal cancer (LARC), only 10-30% of patients achieve pathologic complete response (pCR). The aim of this research was to identify variables for predicting pCR in rectal cancer patients after nCRT. Methods: This retrospective study analyzed 285 LARC patients treated with nCRT and total mesorectal excision (TME). Univariate and multivariate logistic regression was performed to identify the association between clinicopathological characteristics and pCR. A nomogram based on the univariate logistics regression was built to estimate the likelihood of pCR prior to treatment decisions. Results: Univariate logistic regression revealed a significant association between pCR and multiple factors, including histology, CEA levels, clinical N stage, circumferential resection margin (CRM), and the neutrophil-to-lymphocyte ratio (NLR). Upon further multivariate logistic regression, histology, CEA levels, and NLR emerged as the independent predictive factors. A predictive nomogram was developed based on these factors, achieving good predictive ability with an AUC of 0.786. Conclusion: Clinical factors including histology, CEA levels, clinical N stage, circumferential resection margin, and NLR are important predictors of treatment response to nCRT for locally advanced rectal cancer. Furthermore, the developed nomogram aims to facilitate individualized and more effective treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.